Advancements in Clinical Research and Development of Obesity Treatment Medications Weight loss: New drug CagriSema leads to 14% weight loss in trial CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First in Class Twincretin Diabetes Therapy Springer Nature Link Novo Nordisk files for FDA approval of CagriSema, the first once weekly combination of GLP1 and amylin analogues for weight management Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine